Glanbia (GL9) Stock Overview
Operates as a nutrition company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
GL9 Community Fair Values
Create NarrativeSee what 21 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Glanbia plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €21.36 |
| 52 Week High | €22.26 |
| 52 Week Low | €12.00 |
| Beta | 0.52 |
| 1 Month Change | 9.31% |
| 3 Month Change | 24.62% |
| 1 Year Change | 68.99% |
| 3 Year Change | 59.88% |
| 5 Year Change | 50.11% |
| Change since IPO | 1,679.32% |
Recent News & Updates
Narrative Update • Jun 03
GL9: Refined Earnings And Margin Assumptions Will Guide Share Price Direction
The analyst fair value estimate for Glanbia has moved from €20.45 to €22.60, reflecting updated views on revenue growth, margins and valuation after several recent price target adjustments from banks including Deutsche Bank, Morgan Stanley and Mizuho. Analysts broadly point to refined assumptions on the company’s earnings power and appropriate future P/E.
Narrative Update • May 20
GL9: Capital Returns And Whey Input Costs Will Shape Future Share Performance
Glanbia's updated analyst price target has moved from €19.44 to €20.58, reflecting analysts' revised views on margins, growth assumptions and P/E expectations following recent mixed target changes from Morgan Stanley, Deutsche Bank and Mizuho, alongside downgrades from Kepler Cheuvreux and Morgan Stanley. Analyst Commentary Recent research updates on Glanbia present a mix of optimism and caution, with investors weighing improved price targets against concerns around input costs and rating downgrades.Narrative Update • Apr 30
GL9: Capital Returns And Whey Cost Discipline Will Shape Future Share Performance
Analysts have nudged their fair value estimate for Glanbia up from €18.54 to €19.44. This reflects modestly higher assumptions for revenue growth and profit margins, even as recent research highlights concerns over whey input costs and softer Performance Nutrition expectations.
Narrative Update • Apr 16
GL9: Whey Cost Pressures And Capital Returns Will Shape A Balanced Outlook
Narrative Update The analyst price target for Glanbia has been adjusted slightly, reflecting a mix of recent Street research where one firm raised its target by €2 while another trimmed its view by €0.20 and shifted to more neutral ratings as analysts factor in whey input cost pressures on Performance Nutrition volumes and margins. Analyst Commentary Recent Street research on Glanbia has turned more mixed, with a cluster of downgrades and modest price target trims pointing to rising caution around execution and earnings resilience, particularly in Performance Nutrition.Narrative Update • Apr 01
GL9: Higher Whey Costs And Capital Returns Will Shape A Cautious Outlook
Glanbia's updated analyst price target has shifted slightly to €15.63 from €15.72, reflecting mixed recent research in which some analysts cited higher whey input cost concerns for Performance Nutrition, while others modestly increased their targets. Analyst Commentary Recent Street research on Glanbia has been mixed, with some bearish analysts turning more cautious even as others adjust price targets upward.Recent updates
Narrative Update • Jun 03
GL9: Refined Earnings And Margin Assumptions Will Guide Share Price Direction
The analyst fair value estimate for Glanbia has moved from €20.45 to €22.60, reflecting updated views on revenue growth, margins and valuation after several recent price target adjustments from banks including Deutsche Bank, Morgan Stanley and Mizuho. Analysts broadly point to refined assumptions on the company’s earnings power and appropriate future P/E.Narrative Update • May 20
GL9: Capital Returns And Whey Input Costs Will Shape Future Share Performance
Glanbia's updated analyst price target has moved from €19.44 to €20.58, reflecting analysts' revised views on margins, growth assumptions and P/E expectations following recent mixed target changes from Morgan Stanley, Deutsche Bank and Mizuho, alongside downgrades from Kepler Cheuvreux and Morgan Stanley. Analyst Commentary Recent research updates on Glanbia present a mix of optimism and caution, with investors weighing improved price targets against concerns around input costs and rating downgrades.Narrative Update • Apr 30
GL9: Capital Returns And Whey Cost Discipline Will Shape Future Share Performance
Analysts have nudged their fair value estimate for Glanbia up from €18.54 to €19.44. This reflects modestly higher assumptions for revenue growth and profit margins, even as recent research highlights concerns over whey input costs and softer Performance Nutrition expectations.Narrative Update • Apr 16
GL9: Whey Cost Pressures And Capital Returns Will Shape A Balanced Outlook
Narrative Update The analyst price target for Glanbia has been adjusted slightly, reflecting a mix of recent Street research where one firm raised its target by €2 while another trimmed its view by €0.20 and shifted to more neutral ratings as analysts factor in whey input cost pressures on Performance Nutrition volumes and margins. Analyst Commentary Recent Street research on Glanbia has turned more mixed, with a cluster of downgrades and modest price target trims pointing to rising caution around execution and earnings resilience, particularly in Performance Nutrition.Narrative Update • Apr 01
GL9: Higher Whey Costs And Capital Returns Will Shape A Cautious Outlook
Glanbia's updated analyst price target has shifted slightly to €15.63 from €15.72, reflecting mixed recent research in which some analysts cited higher whey input cost concerns for Performance Nutrition, while others modestly increased their targets. Analyst Commentary Recent Street research on Glanbia has been mixed, with some bearish analysts turning more cautious even as others adjust price targets upward.Narrative Update • Mar 18
GL9: Rising Whey Costs Will Pressure Margins And Sustain A Cautious Outlook
Analysts have revised the Glanbia price target higher to about €15.72, from about €14.61. They also pointed to recent downgrades and concerns around rising whey input costs and potential pressure on Performance Nutrition segment volumes and margins.Narrative Update • Mar 04
GL9: Capital Returns And Whey Cost Execution Will Shape Future Upside Potential
Narrative Update on Glanbia The analyst price target for Glanbia has shifted marginally from €18.20 to €18.54, as analysts factor in updated views on whey input costs, Performance Nutrition margins and volumes, as well as revised assumptions for the discount rate, profit margin, revenue growth and future P/E. Analyst Commentary Recent research has focused on how whey input costs could affect Glanbia's Performance Nutrition volumes and margins, and how that feeds through to valuation inputs such as the discount rate, profit margin assumptions, revenue growth and the future P/E applied to the business.Narrative Update • Feb 17
GL9: Execution Risk Around Margins And M&A Will Drive A Cautious Outlook
Analysts have nudged their price target on Glanbia higher by €0.30, citing updated assumptions around fair value, discount rate, revenue growth, profit margins and future P/E that are reflected in the latest Street research. Analyst Commentary Some bearish analysts acknowledge the higher price target but still see reasons to be cautious.Narrative Update • Feb 03
GL9: Capital Returns And Execution On Earnings Framework Will Shape Future Upside Potential
Analysts have nudged their Glanbia price targets slightly higher, with recent research pointing to updated fair value and P/E assumptions, supported by modestly adjusted views on revenue growth and profit margins, and reflected in Street target moves such as Berenberg's shift to €17.90 from €17.05 and Morgan Stanley's recent €0.30 upward revision. Analyst Commentary Recent research updates around Glanbia give you a mixed but useful read on how the Street is thinking about valuation, execution risk, and growth potential, with small price target moves capturing those shifting views.Narrative Update • Jan 20
GL9: Capital Returns And Earnings Delivery Will Drive Future Upside Potential
Glanbia’s updated analyst price target has inched down to about €17.71 from €17.81. This change reflects mixed recent research, with some analysts trimming their targets and others raising theirs, supported by revised assumptions on revenue growth, profit margins and future P/E expectations.Narrative Update • Jan 05
GL9: Execution On Earnings And Capital Deployment Will Shape A Balanced Outlook
Narrative Update on Glanbia The updated analyst price target for Glanbia reflects a recalibration around the recent Street moves, with targets now clustering in the €17.90 to €18.80 range as analysts adjust assumptions for revenue growth, profit margins and the P/E multiple they are willing to apply. Analyst Commentary Recent Street updates on Glanbia remain broadly constructive on the shares, but they also highlight a more measured tone on upside potential.Analysis Article • Dec 26
What You Can Learn From Glanbia plc's (ISE:GL9) P/E
With a price-to-earnings (or "P/E") ratio of 34x Glanbia plc ( ISE:GL9 ) may be sending very bearish signals at the...Narrative Update • Dec 20
GL9: Earnings Execution And Capital Moves Will Shape A Balanced Outlook
Analysts have nudged their price target for Glanbia higher to about EUR 14.92 from roughly EUR 12.27, citing improved expectations for revenue growth, margins, and forward earnings multiples despite some mixed target revisions across the Street. Analyst Commentary Recent Street research on Glanbia reflects a still constructive stance overall, but with a noticeable tilt toward greater valuation discipline.Narrative Update • Dec 05
GL9: Equity Raise Will Drive Future Upside As Earnings Visibility Improves
Analysts have modestly raised their price target on Glanbia to EUR 17.81 from EUR 17.05, reflecting slightly stronger expectations for revenue growth and a marginally higher justified earnings multiple, despite a small downward revision from another firm. Analyst Commentary Recent adjustments to Glanbia's price targets reflect a generally constructive outlook on the company, balanced by some valuation and execution concerns.Narrative Update • Nov 21
GL9: Equity Raise Will Drive Future Opportunity Despite Temporary Index Removal
Analysts have slightly increased their fair value estimate for Glanbia from €17.43 to €17.81. They cite improving revenue growth projections and stronger profit margins in recent research updates.Narrative Update • Nov 06
GL9: Equity Raise and Dividend Increase Will Drive Future Opportunity
Narrative Update on Glanbia: Analyst Price Target Revision Analysts have modestly raised their price target for Glanbia from $16.77 to $17.43. This adjustment is attributed to incremental improvements in profit margin forecasts and slightly higher valuations, even though revenue growth expectations remain softer.Analysis Article • Sep 23
With Glanbia plc (ISE:GL9) It Looks Like You'll Get What You Pay For
With a price-to-earnings (or "P/E") ratio of 34.6x Glanbia plc ( ISE:GL9 ) may be sending very bearish signals at the...Narrative Update • Sep 05
Expanding Health And Dairy Nutrition Will Unlock Global Demand
Glanbia’s significantly lower future P/E multiple, despite stable revenue growth forecasts, suggests a more cautious outlook on valuation, though the consensus analyst price target remains unchanged at €16.77. What's in the News Glanbia will hold an Analyst/Investor Day to update on the Group's medium-term growth agenda.Analysis Article • Aug 16
Glanbia (ISE:GL9) Has Announced A Dividend Of $0.172
The board of Glanbia plc ( ISE:GL9 ) has announced that it will pay a dividend on the 3rd of October, with investors...Analysis Article • Jun 17
Here's Why Glanbia (ISE:GL9) Can Manage Its Debt Responsibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
New Narrative • Mar 02
Digital Transformation And Supply Chain Efficiencies Will Deliver $50 Million Savings By 2027
Glanbia's strategic transformation and segmentation efforts are expected to drive revenue growth and improve profit margins through specialization in high-growth markets.Shareholder Returns
| GL9 | IE Food | IE Market | |
|---|---|---|---|
| 7D | 2.4% | -1.5% | -0.7% |
| 1Y | 69.0% | -8.5% | 13.0% |
Return vs Industry: GL9 exceeded the Irish Food industry which returned -8.5% over the past year.
Return vs Market: GL9 exceeded the Irish Market which returned 13% over the past year.
Price Volatility
| GL9 volatility | |
|---|---|
| GL9 Average Weekly Movement | 4.5% |
| Food Industry Average Movement | 4.5% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in IE Market | 5.7% |
| 10% least volatile stocks in IE Market | 1.6% |
Stable Share Price: GL9 has not had significant price volatility in the past 3 months compared to the Irish market.
Volatility Over Time: GL9's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1964 | 4,963 | Hugh McGuire | www.glanbia.com |
Glanbia plc, together with its subsidiaries, operates as a nutrition company worldwide. The company offers sports nutrition and lifestyle nutrition products in various formats, such as powders, capsules, tablets, ready-to-eat bars, and ready-to-drink beverage. It also manufactures and sells cheese, dairy, and non-dairy nutritional and functional ingredients; and vitamin and mineral premixes products.
Glanbia plc Fundamentals Summary
| GL9 fundamental statistics | |
|---|---|
| Market cap | €5.15b |
| Earnings (TTM) | €159.03m |
| Revenue (TTM) | €3.42b |
32.4x
P/E Ratio1.5x
P/S RatioIs GL9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GL9 income statement (TTM) | |
|---|---|
| Revenue | US$3.95b |
| Cost of Revenue | US$2.88b |
| Gross Profit | US$1.06b |
| Other Expenses | US$878.30m |
| Earnings | US$183.30m |
Last Reported Earnings
Jan 03, 2026
Next Earnings Date
Aug 06, 2026
| Earnings per share (EPS) | 0.76 |
| Gross Margin | 26.90% |
| Net Profit Margin | 4.64% |
| Debt/Equity Ratio | 52.8% |
How did GL9 perform over the long term?
See historical performance and comparisonDividends
2.0%
Current Dividend Yield69%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/07 10:14 |
| End of Day Share Price | 2026/06/05 00:00 |
| Earnings | 2026/01/03 |
| Annual Earnings | 2026/01/03 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Glanbia plc is covered by 19 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alexander Sloane | Barclays |
| Matthew Abraham | Berenberg |
| Fulvio Cazzol | Berenberg |